Aeterna Zentaris Set to Regain Full Rights to Macrilen™ (Macimorelin) in U.S. and Canada from Novo Nordisk

– Company plans to prioritize efforts to identify new strategic development and commercialization partner

– Company is in a strong position that enables it to continue the ongoing pivotal Phase 3 study “DETECT-trial" of macimorelin for the diagnosis of childhood-onset growth hormone deficiency (CGHD)

Read more at globenewswire.com